One In A Million: Aegerion Looks To Raise The Price Of Myalept
This article was originally published in The Pink Sheet Daily
Executive Summary
Company sees “opportunity for a one-time price increase” when it takes over the lipodystrophy drug’s launch from AstraZeneca. At a current cost of about $325,000 per year, metreleptin already is on the ultra-high spectrum on par with other rare disease drugs.
You may also be interested in...
Repurposing Leptin (Part 2): It Really Is A One-In-A-Million Drug
Two decades after the “obesity gene” was the hottest story in biotech, a product from that research is finally going to reach the market. But it is for a disease that occurs in about .0001% of the US population.
Aegerion’s Juxtapid Needs Long-term Post-Market Cohort Study After FDA Nod
Sponsor will institute a registry to monitor patients taking the LDL cholesterol-lowering drug for homozygous familial hypercholesterolemia for 10 years, as part of an approval that is a likely template for Genzyme’s Kynamro.
Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.